Joint association of polymorphism of the FGFR4 gene and mutation TP53 gene with bladder cancer prognosis

Br J Cancer. 2006 Dec 4;95(11):1455-8. doi: 10.1038/sj.bjc.6603456. Epub 2006 Nov 7.

Abstract

The impact of the fibroblast growth factor receptor 4 (FGFR4) Gly388Arg polymorphism on bladder cancer is unknown. We found no clear correlations between the FGFR4 genotype and risk of bladder cancer or pathological parameters. Neither the polymorphism nor TP53 mutation status was an independent predictor of prognosis, but they might act jointly on the disease-specific survival of patients.

Publication types

  • Research Support, N.I.H., Extramural

MeSH terms

  • Aged
  • DNA Mutational Analysis
  • Female
  • Genes, p53 / genetics*
  • Humans
  • Male
  • Middle Aged
  • Mutation
  • Polymorphism, Single Nucleotide / genetics*
  • Prognosis
  • Receptor, Fibroblast Growth Factor, Type 4 / genetics*
  • Survival Analysis
  • Survival Rate
  • Urinary Bladder Neoplasms / genetics*
  • Urinary Bladder Neoplasms / mortality*

Substances

  • FGFR4 protein, human
  • Receptor, Fibroblast Growth Factor, Type 4